MA31624B1 - Utilisation de l'urate oxydase pour le traitement ou la prophylaxie de troubles cardiaques ou de leurs sequelles indirectes causes par des evenements d'ischemie ou de reperfusion - Google Patents

Utilisation de l'urate oxydase pour le traitement ou la prophylaxie de troubles cardiaques ou de leurs sequelles indirectes causes par des evenements d'ischemie ou de reperfusion

Info

Publication number
MA31624B1
MA31624B1 MA32638A MA32638A MA31624B1 MA 31624 B1 MA31624 B1 MA 31624B1 MA 32638 A MA32638 A MA 32638A MA 32638 A MA32638 A MA 32638A MA 31624 B1 MA31624 B1 MA 31624B1
Authority
MA
Morocco
Prior art keywords
treatment
indirect
ischemia
prophylaxis
cardiac
Prior art date
Application number
MA32638A
Other languages
English (en)
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of MA31624B1 publication Critical patent/MA31624B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
    • C12N9/0044—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on other nitrogen compounds as donors (1.7)
    • C12N9/0046—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on other nitrogen compounds as donors (1.7) with oxygen as acceptor (1.7.3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y107/00—Oxidoreductases acting on other nitrogenous compounds as donors (1.7)
    • C12Y107/03—Oxidoreductases acting on other nitrogenous compounds as donors (1.7) with oxygen as acceptor (1.7.3)
    • C12Y107/03003—Factor-independent urate hydroxylase (1.7.3.3), i.e. uricase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

L'INVENTION CONCERNE L'UTILISATION D'UNE URATE-OXYDASE, DE PRÉFÉRENCE UNE URATE-OXYDASE RECOMBINÉE, LA RASBURICASE PAR EXEMPLE, DANS LA PRODUCTION D'UN MÉDICAMENT DESTINÉ À LA PRÉVENTION OU AU TRAITEMENT DE TROUBLES OU DE SÉQUELLES INDIRECTES CARDIAQUES CAUSÉS PAR DES ÉVÉNEMENTS ISCHÉMIQUES OU DE REPERFUSION, PAR EXEMPLE PENDANT ET APRÈS UNE INTERVENTION DE CHIRURGIE CARDIAQUE TELLE QU'UN PONTAGE AORTOCORONARIEN, UNE INTERVENTION CORONARIENNE PERCUTANÉE (ICP), UNE TRANSPLANTATION, APRÈS UN INFARCTUS DU MYOCARDE ET DANS LA PRÉVENTION OU LE TRAITEMENT DE LA CORONAROPATHIE OU DE L'INSUFFISANCE CARDIAQUE, DE L'INSUFFISANCE CARDIAQUE CONGESTIVE PAR EXEMPLE.
MA32638A 2007-09-05 2010-02-22 Utilisation de l'urate oxydase pour le traitement ou la prophylaxie de troubles cardiaques ou de leurs sequelles indirectes causes par des evenements d'ischemie ou de reperfusion MA31624B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07291072 2007-09-05
US1524007P 2007-12-20 2007-12-20

Publications (1)

Publication Number Publication Date
MA31624B1 true MA31624B1 (fr) 2010-08-02

Family

ID=38713162

Family Applications (1)

Application Number Title Priority Date Filing Date
MA32638A MA31624B1 (fr) 2007-09-05 2010-02-22 Utilisation de l'urate oxydase pour le traitement ou la prophylaxie de troubles cardiaques ou de leurs sequelles indirectes causes par des evenements d'ischemie ou de reperfusion

Country Status (22)

Country Link
US (1) US20100266567A1 (fr)
EP (1) EP2197550A1 (fr)
JP (1) JP2011509920A (fr)
KR (1) KR20100053609A (fr)
CN (1) CN101801460A (fr)
AR (1) AR068360A1 (fr)
AU (1) AU2008295145B2 (fr)
BR (1) BRPI0816406A2 (fr)
CA (1) CA2697929A1 (fr)
CL (1) CL2008002623A1 (fr)
CO (1) CO6260090A2 (fr)
IL (1) IL204259A (fr)
MA (1) MA31624B1 (fr)
MX (1) MX2010001976A (fr)
MY (1) MY183770A (fr)
NZ (1) NZ583635A (fr)
PA (1) PA8794801A1 (fr)
PE (1) PE20090642A1 (fr)
TW (1) TW200927929A (fr)
UY (1) UY31320A1 (fr)
WO (1) WO2009030373A1 (fr)
ZA (1) ZA201000774B (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10531655B2 (en) 2011-12-02 2020-01-14 The Regents Of The University Of California Reperfusion protection solution and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5114972A (en) * 1990-07-30 1992-05-19 Tsuyoshi Ohnishi Synthesis and uses of new ascorbic acid derivatives which have anti-oxidant and anti-cancer activities
CA2413201A1 (fr) * 2000-06-28 2002-01-03 Merck & Co., Inc. Traitement de maladie cardio-vasculaire
AU2003275160A1 (en) * 2002-09-20 2004-04-08 Oregon Health And Science University Administration of free radical scavengers to prevent or treat ischemia-reperfusion injuries
MXPA06009072A (es) * 2004-02-09 2007-03-29 Human Genome Sciences Inc Proteinas de fusion de albumina.
WO2005099758A2 (fr) * 2004-04-17 2005-10-27 The Board Of Trustees The Leland Standford Junior University Matrice de tissu bioartificielle injectable
US20070197512A1 (en) * 2006-01-27 2007-08-23 Japan Tobacco Inc. Carboxylic Acid Compounds and Use Thereof

Also Published As

Publication number Publication date
PE20090642A1 (es) 2009-06-18
CL2008002623A1 (es) 2009-01-16
UY31320A1 (es) 2009-04-30
NZ583635A (en) 2011-06-30
CA2697929A1 (fr) 2009-03-12
ZA201000774B (en) 2011-04-28
PA8794801A1 (es) 2009-04-23
CN101801460A (zh) 2010-08-11
AR068360A1 (es) 2009-11-11
MX2010001976A (es) 2010-03-10
AU2008295145A1 (en) 2009-03-12
WO2009030373A1 (fr) 2009-03-12
AU2008295145B2 (en) 2013-12-05
RU2010112867A (ru) 2011-10-10
MY183770A (en) 2021-03-12
US20100266567A1 (en) 2010-10-21
JP2011509920A (ja) 2011-03-31
IL204259A (en) 2013-06-27
CO6260090A2 (es) 2011-03-22
TW200927929A (en) 2009-07-01
EP2197550A1 (fr) 2010-06-23
KR20100053609A (ko) 2010-05-20
BRPI0816406A2 (pt) 2017-05-16

Similar Documents

Publication Publication Date Title
MXPA03010341A (es) Uso de compuestos con actividad inhibitoria de epn/mp combinada en la preparacion de medicamentos.
HK1218548A1 (zh) 脯氨醯羥化酶抑制劑及其使用方法
SG160425A1 (en) Methods, compositions, and formulations for preventing or reducing adverse effects in a patient
YU78703A (sh) Derivati merkaptoacetilamida, postupak za njihovo pripremanje i njihova upotreba
MY183252A (en) Kallirein 7 modulators
MA34483B1 (fr) Traitement de l'hypertension et/ou prévention ou traitement de l'insuffisance cardiaque l'insuffisance cardiaque chez un mammifère recevant une therapie anticoagulante
MA31624B1 (fr) Utilisation de l'urate oxydase pour le traitement ou la prophylaxie de troubles cardiaques ou de leurs sequelles indirectes causes par des evenements d'ischemie ou de reperfusion
HK1107699A1 (en) Ritonavir analogous compound useful as retroviral protease inhibitor, preparation of the ritonavir analogous compound and pharmaceutical composition for the ritonavir analogous compound
MA28081A1 (fr) Nouvelle association d'un anti-atherothrombotique et d'un antiagregant plaquettaire
US20090075976A1 (en) Association between an anti-atherothrombotic and an angiotensin-converting enzyme inhibitor
JP2017530954A5 (fr)
HUP0300730A2 (hu) Eljárás instabil angina pectoris kezelésére
MX2018005359A (es) Pirroloisoindolonas nuevos inhibidores de la enzima convertidora de angiotensina (iecas) para el tratamiento de la hipertension arterial.
MX2022002993A (es) Rebamipida para usarse en la prevencion y/o tratamiento de la rigidez arterial.
TH104398B (th) การใช้ยูเรตออกซิเดสเพื่อการรักษาหรือการป้องกันความผิดปกติหรือผลกระทบทางอ้อมที่ตามมาของหัวใจที่เกิดจากภาวะพร่องเลือดหรือผ่านเลือด
JP2010513300A5 (fr)
WO2021092703A8 (fr) Procédés d'utilisation de colchicine à faible dose après un infarctus du myocarde
NO20034412L (no) Merkaptoacetylamidderivater, fremgangsmåte for deres fremstilling og deresanvendelse
WO2019186442A8 (fr) Combinaison d'un inhibiteur de complexe enzymatique d'ubiquitine-coniuqatinq et de médicaments antihypertenseurs et/ou hypoglycémiques dans une maladie rénale diabétique
MA59341A1 (fr) Analogues de rifamycine et conjugués anticorps-médicament de ceux-ci
Ding et al. Preoperative aspirin and major perioperative outcomes in patients with hypertension undergoing cardiac surgery
Zayani et al. P-166: Involvement of metalloproteinases and their inhibitors in vascular remodeling in hypertensive patients
Kuzmanic et al. Polymorphism of angiotensin-converting enzyme in patients with primary glomerulonephritis and hypertension
MA38789A1 (fr) Composés de pyrimidine-dione contre les affections cardiaques
WO2011004040A3 (fr) Utilisation de captopril en tant qu'élément cardioprotecteur et anti-inflammatoire dans une lésion cardiaque associée à l'hypertension artérielle